Skip to main content
PMC home page
Neuroscience Bulletin logoLink to Neuroscience Bulletin
. 2015 Jan 9;31(1):61–74. doi: 10.1007/s12264-014-1486-4

New hypothesis and treatment targets of depression: an integrated view of key findings

Shangli Cai 1, Shucai Huang 1, Wei Hao 1,✉
PMCID: PMC5562637  PMID: 25575479

Abstract

Major depressive disorder (MDD) is a common and devastating psychiatric disorder characterized by persistent low mood, cognitive disorder, and impaired social function. Despite its complex mechanisms, increasing evidence has identified the involvement of neurotrophic factors, inflammatory cytokines, the hypothalamus-pituitary-adrenal axis, and glutamate receptors in the pathophysiology of this illness. The present review synthesizes recent research achievements to define the network between different hypotheses of MDD and to understand which part is most pivotal for its pathogenesis. By integrating MDD-related signal pathways, we highlight brain-derived neurotrophic factor (BDNF) dysfunction and increased apoptosis as the final common cascades, and new therapeutic strategies aiming to enhance BDNF function have been shown to exert a rapid and effective antidepressant action.

Keywords: depression, BDNF, cytokines, hypothalamus-pituitary-adrenal axis, glutamate receptor

References

  • [1].Knol MJ, Twisk JW, Beekman AT, Heine RJ, Snoek FJ, Pouwer F. Depression as a risk factor for the onset of type 2 diabetes mellitus. A meta-analysis. Diabetologia. 2006;49:837–845. doi: 10.1007/s00125-006-0159-x. [DOI] [PubMed] [Google Scholar]
  • [2].Mathers C, Fat DM, Boerma JT. The global burden of disease: 2004 update. 2008. [Google Scholar]
  • [3].Brundtland GH. From the World Health Organization. Mental health: new understanding, new hope. JAMA. 2001;286:2391. doi: 10.1001/jama.286.19.2391. [DOI] [PubMed] [Google Scholar]
  • [4].Schechter LE, Ring RH, Beyer CE, Hughes ZA, Khawaja X, Malberg JE, et al. Innovative approaches for the development of antidepressant drugs: current and future strategies. NeuroRx. 2005;2:590–611. doi: 10.1602/neurorx.2.4.590. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [5].Block SG, Nemeroff CB. Emerging antidepressants to treat major depressive disorder. Asian J Psychiatr. 2014;12C:7–16. doi: 10.1016/j.ajp.2014.09.001. [DOI] [PubMed] [Google Scholar]
  • [6].Montes JM, Ferrando L, Saiz-Ruiz J. Remission in major depression with two antidepressant mechanisms: results from a naturalistic study. J Affect Disord. 2004;79:229–234. doi: 10.1016/S0165-0327(02)00353-1. [DOI] [PubMed] [Google Scholar]
  • [7].Bortolozzi A, Castane A, Semakova J, Santana N, Alvarado G, Cortes R, et al. New antidepressant strategy based on acute siRNA silencing of 5-HT1A autoreceptors. Mol Psychiatry. 2012;17:567. doi: 10.1038/mp.2012.52. [DOI] [PubMed] [Google Scholar]
  • [8].Assie MB, Lomenech H, Ravailhe V, Faucillon V, Newman-Tancredi A. Rapid desensitization of somatodendritic 5-HT1A receptors by chronic administration of the high-efficacy 5-HT1A agonist, F13714: a microdialysis study in the rat. Br J Pharmacol. 2006;149:170–178. doi: 10.1038/sj.bjp.0706859. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [9].Duman RS, Li N. A neurotrophic hypothesis of depression: role of synaptogenesis in the actions of NMDA receptor antagonists. Philos Trans R Soc Lond B Biol Sci. 2012;367:2475–2484. doi: 10.1098/rstb.2011.0357. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [10].Neto FL, Borges G, Torres-Sanchez S, Mico JA, Berrocoso E. Neurotrophins role in depression neurobiology: a review of basic and clinical evidence. Curr Neuropharmacol. 2011;9:530–552. doi: 10.2174/157015911798376262. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [11].Holtzman DM, Mobley WC. Neurotrophic factors and neurologic disease. West J Med. 1994;161:246–254. [PMC free article] [PubMed] [Google Scholar]
  • [12].Russo-Neustadt A, Ha T, Ramirez R, Kesslak JP. Physical activity-antidepressant treatment combination: impact on brain-derived neurotrophic factor and behavior in an animal model. Behav Brain Res. 2001;120:87–95. doi: 10.1016/S0166-4328(00)00364-8. [DOI] [PubMed] [Google Scholar]
  • [13].Karege F, Perret G, Bondolfi G, Schwald M, Bertschy G, Aubry JM. Decreased serum brain-derived neurotrophic factor levels in major depressed patients. Psychiatry Res. 2002;109:143–148. doi: 10.1016/S0165-1781(02)00005-7. [DOI] [PubMed] [Google Scholar]
  • [14].Duman RS, Malberg J, Nakagawa S, D’Sa C. Neuronal plasticity and survival in mood disorders. Biol Psychiatry. 2000;48:732–739. doi: 10.1016/S0006-3223(00)00935-5. [DOI] [PubMed] [Google Scholar]
  • [15].Nibuya M, Morinobu S, Duman RS. Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments. J Neurosci. 1995;15:7539–7547. doi: 10.1523/JNEUROSCI.15-11-07539.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [16].Siuciak JA, Lewis DR, Wiegand SJ, Lindsay RM. Antidepressant-like effect of brain-derived neurotrophic factor (BDNF) Pharmacol Biochem Behav. 1997;56:131–137. doi: 10.1016/S0091-3057(96)00169-4. [DOI] [PubMed] [Google Scholar]
  • [17].Sarchiapone M, Carli V, Roy A, Iacoviello L, Cuomo C, Latella MC, et al. Association of polymorphism (Val66Met) of brain-derived neurotrophic factor with suicide attempts in depressed patients. Neuropsychobiology. 2008;57:139–145. doi: 10.1159/000142361. [DOI] [PubMed] [Google Scholar]
  • [18].Dwivedi Y. Brain-derived neurotrophic factor in suicide pathophysiology. In: Dwivedi Y, editor. The Neurobiological Basis of Suicide. Boca Raton (FL): CRC Press; 2012. [PubMed] [Google Scholar]
  • [19].Kanellopoulos D, Gunning FM, Morimoto SS, Hoptman MJ, Murphy CF, Kelly RE, et al. Hippocampal volumes and the brain-derived neurotrophic factor val66met polymorphism in geriatric major depression. Am J Geriatr Psychiatry. 2011;19:13–22. doi: 10.1097/JGP.0b013e3181f61d62. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [20].Carvalho AL, Caldeira MV, Santos SD, Duarte CB. Role of the brain-derived neurotrophic factor at glutamatergic synapses. Br J Pharmacol. 2008;153(Suppl1):S310–324. doi: 10.1038/sj.bjp.0707509. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [21].Altar CA. Neurotrophins and depression. Trends Pharmacol Sci. 1999;20:59–61. doi: 10.1016/S0165-6147(99)01309-7. [DOI] [PubMed] [Google Scholar]
  • [22].Duman RS, Monteggia LM. A neurotrophic model for stress-related mood disorders. Biol Psychiatry. 2006;59:1116–1127. doi: 10.1016/j.biopsych.2006.02.013. [DOI] [PubMed] [Google Scholar]
  • [23].Almeida RD, Manadas BJ, Melo CV, Gomes JR, Mendes CS, Graos MM, et al. Neuroprotection by BDNF against glutamate-induced apoptotic cell death is mediated by ERK and PI3-kinase pathways. Cell Death Differ. 2005;12:1329–1343. doi: 10.1038/sj.cdd.4401662. [DOI] [PubMed] [Google Scholar]
  • [24].Lu B. BDNF an d activity-dependent synaptic modulation. Learn Mem. 2003;10:86–98. doi: 10.1101/lm.54603. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [25].Duncan WC, Jr., Zarate CA., Jr. Ketamine, sleep, and depression: current status and new questions. Curr Psychiatry Rep. 2013;15:394. doi: 10.1007/s11920-013-0394-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [26].Faraguna U, Vyazovskiy VV, Nelson AB, Tononi G, Cirelli C. A causal role for brain-derived neurotrophic factor in the homeostatic regulation of sleep. J Neurosci. 2008;28:4088–4095. doi: 10.1523/JNEUROSCI.5510-07.2008. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [27].Huber R, Tononi G, Cirelli C. Exploratory behavior, cortical BDNF expression, and sleep homeostasis. Sleep. 2007;30:129–139. doi: 10.1093/sleep/30.2.129. [DOI] [PubMed] [Google Scholar]
  • [28].Laje G, Lally N, Mathews D, Brutsche N, Chemerinski A, Akula N, et al. Brain-derived neurotrophic factor Val66Met polymorphism and antidepressant efficacy of ketamine in depressed patients. Biol Psychiatry. 2012;72:e27–28. doi: 10.1016/j.biopsych.2012.05.031. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [29].Bachmann V, Klein C, Bodenmann S, Schafer N, Berger W, Brugger P, et al. The BDNF Val66Met polymorphism modulates sleep intensity: EEG frequency- and state-specificity. Sleep. 2012;35:335–344. doi: 10.5665/sleep.1690. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [30].Barker PA. Whither proBDNF? Nat Neurosci. 2009;12:105–106. doi: 10.1038/nn0209-105. [DOI] [PubMed] [Google Scholar]
  • [31].Hashimoto K. Sigma-1 receptor chaperone and brain-derived neurotrophic factor: emerging links between cardiovascular disease and depression. Prog Neurobiol. 2013;100:15–29. doi: 10.1016/j.pneurobio.2012.09.001. [DOI] [PubMed] [Google Scholar]
  • [32].Kikuchi-Utsumi K, Nakaki T. Chronic treatment with a selective ligand for the sigma-1 receptor chaperone, SA4503, up-regulates BDNF protein levels in the rat hippocampus. Neurosci Lett. 2008;440:19–22. doi: 10.1016/j.neulet.2008.05.055. [DOI] [PubMed] [Google Scholar]
  • [33].Fujimoto M, Hayashi T, Urfer R, Mita S, Su TP. Sigma-1 receptor chaperones regulate the secretion of brain-derived neurotrophic factor. Synapse. 2012;66:630–639. doi: 10.1002/syn.21549. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [34].Bergeron R, de Montigny C, Debonnel G. Potentiation of neuronal NMDA response induced by dehydroepiandrosterone and its suppression by progesterone: effects mediated via sigma receptors. J Neurosci. 1996;16:1193–1202. doi: 10.1523/JNEUROSCI.16-03-01193.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [35].Sabino V, Cottone P, Parylak SL, Steardo L, Zorrilla EP. Sigma-1 receptor knockout mice display a depressive-like phenotype. Behav Brain Res. 2009;198:472–476. doi: 10.1016/j.bbr.2008.11.036. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [36].Ukai M, Maeda H, Nanya Y, Kameyama T, Matsuno K. Beneficial effects of acute and repeated administrations of sigma receptor agonists on behavioral despair in mice exposed to tail suspension. Pharmacol Biochem Behav. 1998;61:247–252. doi: 10.1016/S0091-3057(98)00093-8. [DOI] [PubMed] [Google Scholar]
  • [37].Kobayashi T, Matsuno K, Murai M, Mita S. Sigma 1 receptor subtype is involved in the facilitation of cortical dopaminergic transmission in the rat brain. Neurochem Res. 1997;22:1105–1109. doi: 10.1023/A:1027361101419. [DOI] [PubMed] [Google Scholar]
  • [38].Peyron C, Petit JM, Rampon C, Jouvet M, Luppi PH. Forebrain afferents to the rat dorsal raphe nucleus demonstrated by retrograde and anterograde tracing methods. Neuroscience. 1998;82:443–468. doi: 10.1016/S0306-4522(97)00268-6. [DOI] [PubMed] [Google Scholar]
  • [39].Kulkarni SK, Dhir A. sigma-1 receptors in major depression and anxiety. Expert Rev Neurother. 2009;9:1021–1034. doi: 10.1586/ern.09.40. [DOI] [PubMed] [Google Scholar]
  • [40].Han QQ, Yu J. Inflammation: a mechanism of depression? Neurosci Bull. 2014;30:515–523. doi: 10.1007/s12264-013-1439-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [41].Hashmi AM, Butt Z, Umair M. Is depression an inflammatory condition? A review of available evidence. J Pak Med Assoc. 2013;63:899–906. [PubMed] [Google Scholar]
  • [42].Anisman H, Hayley S. Inflammatory factors contribute to depression and its comorbid conditions. Sci Signal. 2012;5:pe45. doi: 10.1126/scisignal.2003579. [DOI] [PubMed] [Google Scholar]
  • [43].Lopresti AL, Maker GL, Hood SD, Drummond PD. A review of peripheral biomarkers in major depression: the potential of inflammatory and oxidative stress biomarkers. Prog Neuropsychopharmacol Biol Psychiatry. 2014;48:102–111. doi: 10.1016/j.pnpbp.2013.09.017. [DOI] [PubMed] [Google Scholar]
  • [44].Spedding M, Gressens P. Neurotrophins and cytokines in neuronal plasticity. Novartis Found Symp. 2008;289:222–233. doi: 10.1002/9780470751251.ch18. [DOI] [PubMed] [Google Scholar]
  • [45].Hayley S, Poulter MO, Merali Z, Anisman H. The pathogenesis of clinical depression: stressor- and cytokine-induced alterations of neuroplasticity. Neuroscience. 2005;135:659–678. doi: 10.1016/j.neuroscience.2005.03.051. [DOI] [PubMed] [Google Scholar]
  • [46].Na KS, Lee KJ, Lee JS, Cho YS, Jung HY. Efficacy of adjunctive celecoxib treatment for patients with major depressive disorder: a meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry. 2014;48:79–85. doi: 10.1016/j.pnpbp.2013.09.006. [DOI] [PubMed] [Google Scholar]
  • [47].Pace TW, Hu F, Miller AH. Cytokine-effects on glucocorticoid receptor function: relevance to glucocorticoid resistance and the pathophysiology and treatment of major depression. Brain Behav Immun. 2007;21:9–19. doi: 10.1016/j.bbi.2006.08.009. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [48].Li WZ, Li WP, Yao YY, Zhang W, Yin YY, Wu GC, et al. Glucocorticoids increase impairments in learning and memory due to elevated amyloid precursor protein expression and neuronal apoptosis in 12-month old mice. Eur J Pharmacol. 2010;628:108–115. doi: 10.1016/j.ejphar.2009.11.045. [DOI] [PubMed] [Google Scholar]
  • [49].Miller AH, Maletic V, Raison CL. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol Psychiatry. 2009;65:732–741. doi: 10.1016/j.biopsych.2008.11.029. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [50].Ida T, Hara M, Nakamura Y, Kozaki S, Tsunoda S, Ihara H. Cytokine-induced enhancement of calcium-dependent glutamate release from astrocytes mediated by nitric oxide. Neurosci Lett. 2008;432:232–236. doi: 10.1016/j.neulet.2007.12.047. [DOI] [PubMed] [Google Scholar]
  • [51].Maciejewski PK, Rothman DL. Proposed cycles for functional glutamate trafficking in synaptic neurotransmission. Neurochem Int. 2008;52:809–825. doi: 10.1016/j.neuint.2007.09.015. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [52].Kapczinski F, Frey BN, Andreazza AC, Kauer-Sant’Anna M, Cunha AB, Post RM. Increased oxidative stress as a mechanism for decreased BDNF levels in acute manic episodes. Rev Bras Psiquiatr. 2008;30:243–245. doi: 10.1590/S1516-44462008000300011. [DOI] [PubMed] [Google Scholar]
  • [53].Lee B, Cao R, Choi YS, Cho HY, Rhee AD, Hah CK, et al. The CREB/CRE transcriptional pathway: protection against oxidative stress-mediated neuronal cell death. J Neurochem. 2009;108:1251–1265. doi: 10.1111/j.1471-4159.2008.05864.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [54].Hardingham GE, Fukunaga Y, Bading H. Extrasynaptic NMDARs oppose synaptic NMDARs by triggering CREB shut-off and cell death pathways. Nat Neurosci. 2002;5:405–414. doi: 10.1038/nn835. [DOI] [PubMed] [Google Scholar]
  • [55].Yuen EY, Wei J, Liu W, Zhong P, Li X, Yan Z. Repeated stress causes cognitive impairment by suppressing glutamate receptor expression and function in prefrontal cortex. Neuron. 2012;73:962–977. doi: 10.1016/j.neuron.2011.12.033. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [56].Beneyto M, Kristiansen LV, Oni-Orisan A, McCullumsmith RE, Meador-Woodruff JH. Abnormal glutamate receptor expression in the medial temporal lobe in schizophrenia and mood disorders. Neuropsychopharmacology. 2007;32:1888–1902. doi: 10.1038/sj.npp.1301312. [DOI] [PubMed] [Google Scholar]
  • [57].Koike H, Iijima M, Chaki S. Involvement of AMPA receptor in both the rapid and sustained antidepressant-like effects of ketamine in animal models of depression. Behav Brain Res. 2011;224:107–111. doi: 10.1016/j.bbr.2011.05.035. [DOI] [PubMed] [Google Scholar]
  • [58].Koike H, Fukumoto K, Iijima M, Chaki S. Role of BDNF/TrkB signaling in antidepressant-like effects of a group II metabotropic glutamate receptor antagonist in animal models of depression. Behav Brain Res. 2013;238:48–52. doi: 10.1016/j.bbr.2012.10.023. [DOI] [PubMed] [Google Scholar]
  • [59].Hashimoto K. Role of the mTOR signaling pathway in the rapid antidepressant action of ketamine. Expert Rev Neurother. 2011;11:33–36. doi: 10.1586/ern.10.176. [DOI] [PubMed] [Google Scholar]
  • [60].Monteggia LM, Gideons E, Kavalali ET. The role o f eukaryotic elongation factor 2 kinase in rapid antidepressant action of ketamine. Biol Psychiatry. 2013;73:1199–1203. doi: 10.1016/j.biopsych.2012.09.006. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [61].Beurel E, Song L, Jope RS. Inhibition of glycogen synthase kinase-3 is necessary for the rapid antidepressant effect of ketamine in mice. Mol Psychiatry. 2011;16:1068–1070. doi: 10.1038/mp.2011.47. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [62].Chen BY, Wang X, Wang ZY, Wang YZ, Chen LW, Luo ZJ. Brain-derived neurotrophic factor stimulates proliferation and differentiation of neural stem cells, possibly by triggering the Wnt/beta-catenin signaling pathway. J Neurosci Res. 2013;91:30–41. doi: 10.1002/jnr.23138. [DOI] [PubMed] [Google Scholar]
  • [63].Kapur S, Seeman P. NMDA receptor antagonists ketamine and PCP have direct effects on the dopamine D(2) and serotonin 5-HT(2)receptors-implications for models of schizophrenia. Mol Psychiatry. 2002;7:837–844. doi: 10.1038/sj.mp.4001093. [DOI] [PubMed] [Google Scholar]
  • [64].Zugno AI, Juliao RF, Budni J, Volpato AM, Fraga DB, Pacheco FD, et al. Rivastigmine reverses cognitive deficit and acetylcholinesterase activity induced by ketamine in an animal model of schizophrenia. Metab Brain Dis. 2013;28:501–508. doi: 10.1007/s11011-013-9417-z. [DOI] [PubMed] [Google Scholar]
  • [65].Ago Y, Yano K, Araki R, Hiramatsu N, Kita Y, Kawasaki T, et al. Metabotropic glutamate 2/3 receptor antagonists improve behavioral and prefrontal dopaminergic alterations in the chronic corticosterone-induced depression model in mice. Neuropharmacology. 2013;65:29–38. doi: 10.1016/j.neuropharm.2012.09.008. [DOI] [PubMed] [Google Scholar]
  • [66].Dwyer JM, Lepack AE, Duman RS. mTOR activation is required for the antidepressant effects of mGluR(2)/(3) blockade. Int J Neuropsychopharmacol. 2012;15:429–434. doi: 10.1017/S1461145711001702. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [67].Burgdorf J, Zhang XL, Nicholson KL, Balster RL, Leander JD, Stanton PK, et al. GLYX-13, a NMDA receptor glycine-site functional partial agonist, induces antidepressant-like effects without ketamine-like side effects. Neuropsychopharmacol. 2013;38:729–742. doi: 10.1038/npp.2012.246. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [68].Moskal JR, Burch R, Burgdorf JS, Kroes RA, Stanton PK, Disterhoft JF, et al. GLYX-13, an NMDA receptor glycine site functional partial agonist enhances cognition and produces antidepressant effects without the psychotomimetic side effects of NMDA receptor antagonists. Expert Opin Investig Drugs. 2014;23:243–254. doi: 10.1517/13543784.2014.852536. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [69].Black PH. Stress and the inflammatory response: a review of neurogenic inflammation. Brain Behav Immun. 2002;16:622–653. doi: 10.1016/S0889-1591(02)00021-1. [DOI] [PubMed] [Google Scholar]
  • [70].Kumamaru E, Numakawa T, Adachi N, Kunugi H. Glucocorticoid suppresses BDNF-stimulated MAPK/ERK pathway via inhibiting interaction of Shp2 with TrkB. FEBS Lett. 2011;585:3224–3228. doi: 10.1016/j.febslet.2011.09.010. [DOI] [PubMed] [Google Scholar]
  • [71].Wosiski-Kuhn M, Erion JR, Gomez-Sanchez EP, Gomez-Sanchez CE, Stranahan AM. Glucocorticoid receptor activation impairs hippocampal plasticity by suppressing BDNF expression in obese mice. Psychoneuroendocrinology. 2014;42:165–177. doi: 10.1016/j.psyneuen.2014.01.020. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [72].Zhang J, Fan Y, Li Y, Zhu H, Wang L, Zhu MY. Chronic social defeat up-regulates expression of the serotonin transporter in rat dorsal raphe nucleus and projection regions in a glucocorticoid-dependent manner. J Neurochem. 2012;123:1054–1068. doi: 10.1111/jnc.12055. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [73].Kling MA, Coleman VH, Schulkin J. Glucocorticoid inhibition in the treatment of depression: can we think outside the endocrine hypothalamus? Depress Anxiety. 2009;26:641–649. doi: 10.1002/da.20546. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [74].Calandra T, Bernhagen J, Metz CN, Spiegel LA, Bacher M, Donnelly T, et al. MIF as a glucocorticoid-induced modulator of cytokine production. Nature. 1995;377:68–71. doi: 10.1038/377068a0. [DOI] [PubMed] [Google Scholar]
  • [75].Jing L, Bu M. Role of macrophage migration inhibitory factor in glucocorticoid release and glucocorticoid receptor function in rats. Ann Clin Lab Sci. 2011;41:14–19. [PubMed] [Google Scholar]
  • [76].Edwards KM, Bosch JA, Engeland CG, Cacioppo JT, Marucha PT. Elevated macrophage migration inhibitory factor (MIF) is associated with depressive symptoms, blunted cortisol reactivity to acute stress, and lowered morning cortisol. Brain Behav Immun. 2010;24:1202–1208. doi: 10.1016/j.bbi.2010.03.011. [DOI] [PubMed] [Google Scholar]
  • [77].Cattaneo A, Gennarelli M, Uher R, Breen G, Farmer A, Aitchison K J, et al. Candidate genes expression profile associated with antidepressants response in the GENDEP study: differentiating between baseline ‘predictors’ and longitudinal ‘targets’. Neuropsychopharmacol. 2013;38:377–385. doi: 10.1038/npp.2012.191. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [78].Conboy L, Varea E, Castro JE, Sakouhi-Ouertatani H, Calandra T, Lashuel HA, et al. Macrophage migration inhibitory factor is critically involved in basal and fluoxetine-stimulated adult hippocampal cell proliferation and in anxiety, depression, and memory-related behaviors. Mol Psychiatry. 2011;16:533–547. doi: 10.1038/mp.2010.15. [DOI] [PubMed] [Google Scholar]
  • [79].Moon HY, Kim SH, Yang YR, Song P, Yu HS, Park HG, et al. Macrophage migration inhibitory factor mediates the antidepressant actions of voluntary exercise. Proc Natl Acad Sci U S A. 2012;109:13094–13099. doi: 10.1073/pnas.1205535109. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [80].Quera Salva MA, Hartley S, Barbot F, Alvarez JC, Lofaso F, Guilleminault C. Circadian rhythms, melatonin and depression. Curr Pharm Des. 2011;17:1459–1470. doi: 10.2174/138161211796197188. [DOI] [PubMed] [Google Scholar]
  • [81].Murray G. Diurnal mood variation in depression: a signal of disturb ed circadian function? J Affect Disord. 2007;102:47–53. doi: 10.1016/j.jad.2006.12.001. [DOI] [PubMed] [Google Scholar]
  • [82].Suchecki D, Tiba PA, Machado RB. REM Sleep Rebound as an Adaptive Response to Stressful Situations. Front Neurol. 2012;3:41. doi: 10.3389/fneur.2012.00041. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [83].Beck-Friis J, Kjellman BF, Aperia B, Unden F, von Rosen D, Ljunggren JG, et al. Serum melatonin in relation to clinical variables in patients with major depressive disorder and a hypothesis of a low melatonin syndrome. Acta Psychiatr Scand. 1985;71:319–330. doi: 10.1111/j.1600-0447.1985.tb02531.x. [DOI] [PubMed] [Google Scholar]
  • [84].Khaleghipour S, Masjedi M, Ahade H, Enayate M, Pasha G, Nadery F, et al. Morning and nocturnal serum melatonin rhythm levels in patients with major depressive disorder: an analytical cross-sectional study. Sao Paulo Med J. 2012;130:167–172. doi: 10.1590/S1516-31802012000300006. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [85].Monteleone P, Martiadis V, Maj M. Circadian rhythms and treatment implications in depression. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35:1569–1574. doi: 10.1016/j.pnpbp.2010.07.028. [DOI] [PubMed] [Google Scholar]
  • [86].Gulec M, Selvi Y, Boysan M, Aydin A, Besiroglu L, Agargun MY. Ongoing or re-emerging subjective insomnia symptoms after full/partial remission or recovery of major depressive disorder mainly with the selective serotonin reuptake inhibitors and risk of relapse or recurrence: a 52-week follow-up study. J Affect Disord. 2011;134:257–265. doi: 10.1016/j.jad.2011.05.056. [DOI] [PubMed] [Google Scholar]
  • [87].Campino C, Valenzuela FJ, Torres-Farfan C, Reynolds HE, Abarzua-Catalan L, Arteaga E, et al. Melatonin exerts direct inhibitory actions on ACTH responses in the human adrenal gland. Horm Metab Res. 2011;43:337–342. doi: 10.1055/s-0031-1271693. [DOI] [PubMed] [Google Scholar]
  • [88].Konakchieva R, Mitev Y, Almeida OF, Patchev VK. Chronic melatonin treatment counteracts glucocorticoid-induced dysregulation of the hypothalamic-pituitary-adrenal axis in the rat. Neuroendocrinology. 1998;67:171–180. doi: 10.1159/000054312. [DOI] [PubMed] [Google Scholar]
  • [89].Avery D, Lenz M, Landis C. Guidelines for prescribing melatonin. Ann Med. 1998;30:122–130. doi: 10.3109/07853899808999394. [DOI] [PubMed] [Google Scholar]
  • [90].Germain A, Kupfer DJ. Circadian rhythm disturbances in depression. Hum Psychopharmacol. 2008;23:571–585. doi: 10.1002/hup.964. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Neuroscience Bulletin are provided here courtesy of Springer

RESOURCES